AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06082063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone
Description: Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (>30 mg/g) despite RAS blockade.
Study NCT05375955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.01%
Description: Atopic Dermatitis and Plaque Psoriasis
Study NCT05375955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Atopic Dermatitis and Plaque Psoriasis
Study NCT05375955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.03%
Description: Atopic Dermatitis and Plaque Psoriasis
Study NCT05375955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.06%
Description: PF-07038124 ointment 0.06% (Plaque Psoriasis only)
Study NCT06416111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
Study NCT06416111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinprick Test
Description: With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling
Study NCT06416111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Bromage Scale
Description: Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers.
Study NCT06416111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
Study NCT06416111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
Study NCT05374525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE
Description: Available as intramuscular injection.
Study NCT04203199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real rTMS to the dlPFC using H1 Coil
Description: This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
Study NCT05374525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir OLI
Description: Available as marketed orally administered tablets.
Study NCT05136196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsies
Study NCT05136196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05136196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05136196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT05136196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans
Study NCT05136196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05576727 — intervention group
Intervention type: OTHER
Intervention: Unruptured intracranial aneurysms
Description: Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
Study NCT06280950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.
Study NCT06280950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (continued reduction)
Description: * Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction
Study NCT06280950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (maintain 50% reduction)
Description: - Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Study NCT06280950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen.
Study NCT05493696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill
Description: Alter G training for 30-minute, 3 times/week, 75% body weight
Study NCT05493696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: applied 3 times/week for 12 weeks
Study NCT05493696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: applied 3 times/week for 12 weeks
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Phentermine-Topiramate combination
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Phentermine
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Tirzepatide
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Topiramate
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Diethylpropion
Description: Medication for weight loss
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Naltrexone/Bupropion
Description: Medication for weight loss
Study NCT05657548 — intervention group
Intervention type: RADIATION
Intervention: spine and pelvis radiography
Description: X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
Study NCT05722067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium ionophore
Description: The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
Study NCT05796609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving under the influence of alcohol
Description: Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration
Study NCT05796609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Driving under the influence of a placebo
Description: Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration
Study NCT04915807 — intervention group
Intervention type: DRUG
Intervention: Ramucirumab and paclitaxel
Description: Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
Study NCT04915807 — intervention group
Intervention type: DRUG
Intervention: Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy
Description: Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
Study NCT05722509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Flap Reduction Group
Description: A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
Study NCT05722509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only Exodontia Group
Description: Third molar exodontia without associated surgery.
Study NCT05756764 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Medication for weight loss
Study NCT06578715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
Study NCT06577584 — intervention group
Intervention type: OTHER
Intervention: Follow-up in the Diabetes Care Trajectory
Description: Being followed-up in the Diabetes Care Trajectory in Belgium
Study NCT06577584 — intervention group
Intervention type: OTHER
Intervention: Follow-up in the Diabetes Convention
Description: Being followed-up in the Diabetes Convention in Belgium
Study NCT04886960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Injection
Description: Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
Study NCT05045209 — intervention group
Intervention type: OTHER
Intervention: Virtual rehabilitation
Description: Patient who are assigned to this group will receive virtual rehabilitation
Study NCT04886960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
Study NCT06502327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions A
Description: Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins.
Study NCT06502327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructions B
Description: Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins.
Study NCT05018481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
Study NCT05018481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given in capsule form to study participants
Study NCT04929951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro Fragmented Adipose Tissue
Description: Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
Study NCT04929951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
Study NCT04944706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time
Description: Take 3 times a day after meals,24 weeks
Study NCT04944706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills 4 bags/time
Description: Take 3 times a day after meals,24 weeks
Study NCT04944706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills placebo 4 bags/time
Description: Take 3 times a day after meals,24 weeks
Study NCT05783102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge and Interpersonal Skills to Develop Exemplary Relationships
Description: During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
Study NCT06503692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKutting PTA Scoring Balloon Dilatation Catheter
Description: The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.
Study NCT06503692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Catheter
Description: The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.
Study NCT05008835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose A
Description: Oral dose of ACP-044 Dose A
Study NCT05008835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose B
Description: Oral dose of ACP-044 Dose B
Study NCT05008835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04616014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 QD
Description: 16 mg, QD, two capsules, 8 mg each.
Study NCT05124093 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Apnoeic oxygenation
Description: After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%.
Study NCT04758936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
Study NCT04758936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
Study NCT05124093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apnoeic oxygenation
Description: After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%.
Study NCT06209970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35
Description: All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
Study NCT06519968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).
Study NCT05180864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: Open or minimally invasive (sub)total gastrectomy
Study NCT06220175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strepsils Intensiv plus Xilocaine spray Arm
Description: After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
Study NCT05180864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Open or minimally invasive (sub)total gastrectomy
Study NCT06519968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as DPI.
Study NCT06647082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Knee Exoskeleton
Description: The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
Study NCT05127174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
Study NCT04775706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912 Active
Description: Randomized, double-blind, placebo-controlled
Study NCT04775706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized, double-blind, placebo-controlled